DI NICOLANTONIO, Federica

DI NICOLANTONIO, Federica

Rete di Collaborazioni Statistiche Email Alert RSS Feed

Pubblicazioni

Risultati 1 - 20 di 130 (tempo di esecuzione: 0.0 secondi).

TitoloData di pubblicazioneAutore(i)
1A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer2011Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A†; Trusolino L† (†Co-Senior authors)
2A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility2016Vecchione, Loredana; Gambino, Valentina; Raaijmakers, Jonne; Schlicker, Andreas; Fumagalli, Arianna; Russo, Mariangela; Villanueva, Alberto; Beerling, Evelyne; Bartolini, Alice; Mollevi, David G.; El-Murr, Nizar; Chiron, Marielle; Calvet, Loreley; Nicolazzi, Céline; Combeau, Cécile; Henry, Christophe; Simon, Iris M.; Tian, Sun; In 'T Veld, Sjors; D'Ario, Giovanni; Mainardi, Sara; Beijersbergen, Roderick L.; Lieftink, Cor; Linn, Sabine; Rumpf-Kienzl, Cornelia; Delorenzi, Mauro; Wessels, Lodewyk; Salazar, Ramon; Di Nicolantonio, Federica; Bardelli, Alberto; Van Rheenen, Jacco; Medema, René H.; Tejpar, Sabine; Bernards, René
3Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas2003Edmunds SC; Cree IA; Di Nicolantonio F; Hungerford JL; Hurren JS; Kelsell DP
4Abstract 1163: Microenvironment targets in KRAS-mutated metastatic colorectal cancer2014Marchio, Serena; Bartolini, Alice; Cardaci, Sabrina; Soster, Marco; Corti, Giorgio; Lamba, Simona; Bussolino, Federico; Cora', Davide; Di Nicolantonio, Federica
5Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer2016Van Emburgh, Beth O; Arena, Sabrina; Siravegna, Giulia; Lazzari, Luca; Crisafulli, Giovanni; Corti, Giorgio; Mussolin, Benedetta; Baldi, Federica; Buscarino, Michela; Bartolini, Alice; Valtorta, Emanuele; Vidal, Joana; Bellosillo, Beatriz; Germano, Giovanni; Pietrantonio, Filippo; Ponzetti, Agostino; Albanell, Joan; Siena, Salvatore; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Montagut, Clara; Bardelli, Alberto
6Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells2012Hobor S; Misale S; Crowley E; Scala E; Zanon C; Di Nicolantonio F; Bardelli A
7Acquired resistance to EGFR-targeted therapies in colorectal cancer.2014Van Emburgh BO;Sartore-Bianchi A;Di Nicolantonio F;Siena S;Bardelli A
8Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer2016Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice; Cam, Nicholas; Patel, Roopal; Yan, Shunqi; Shoemaker, Robert; Wild, Robert; Di Nicolantonio, Federica; Sartore-Bianchi, Andrea; Li, Gang; Siena, Salvatore; Bardelli, Alberto
9Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling2018Carbone, C; Piro, G; Gaianigo, N; Ligorio, F; Santoro, R; Merz, V; Simionato, F; Zecchetto, C; Falco, G; Conti, G; Kamga, P T; Krampera, M; Di Nicolantonio, F; De Franceschi, L; Scarpa, A; Tortora, G; Melisi, D
10ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer2017Pietrantonio, Filippo*; Di Nicolantonio, Federica*; Schrock, Alexa B; Lee, Jeeyun; Tejpar, Sabine; Sartore-Bianchi, Andrea; Hechtman, Jaclyn F; Christiansen, Jason; Novara, Luca; Tebbutt, Niall; Fucà, Giovanni; Antoniotti, Carlotta; Kim, Seung Tae; Murphy, Danielle; Berenato, Rosa; Morano, Federica; Sun, James; Min, Bosun; Stephens, Philip J; Chen, Marissa; Lazzari, Luca; Miller, Vincent A; Shoemaker, Robert; Amatu, Alessio; Milione, Massimo; Ross, Jeffrey S; Siena, Salvatore; Bardelli, Alberto; Ali, Siraj M; Falcone, Alfredo; de Braud, Filippo; Cremolini, Chiara; *corresponding authors
11Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer.2013Bardelli A*;Corso S*;Bertotti A*;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S (*Co-First Authors)
12Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues2006Salvatore Siena; Mauro Moroni; Giovanna Marrapese; Andrea Sartore-Bianchi; Silvio Veronese; Marcello Gambacorta; Silvia Benvenuti; Federica Di Nicolantonio; Alberto Bardelli
13Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.2010De Roock, W;* Jonker, Dj;* Di Nicolantonio, F; * Sartore-Bianchi, A; Tu, D; Siena, S; Lamba, S; Arena, S; Frattini, M; Piessevaux, H; Van Cutsem, E; O'Callaghan, Cj; Khambata-Ford, S; Zalcberg, Jr; Simes, J; Karapetis, Cs; Bardelli, A; Tejpar, S. (*co-first authorship)
14BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer2016Bartolini, A; Cardaci, S; Lamba, S; Oddo, D; Marchiò, C; Cassoni, P; Amoreo, Ca; Corti, G; Testori, A; Bussolino, F; Pasqualini, R; Arap, W; Corà, D; Di Nicolantonio, F*; Marchiò, S.; *co-last authors and corresponding authors
15Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer2018Dunne, Philip D.*; Coleman, Helen G.; Bankhead, Peter; Alderdice, Matthew; Gray, Ronan T.; McQuaid, Stephen; Bingham, Victoria; Loughrey, Maurice B.; James, Jacqueline A.; McCorry, Amy M.B.; Gilmore, Alan; Holohan, Caitriona; Klingbiel, Dirk; Tejpar, Sabine; Johnston, Patrick G.; McArt, Darragh G.; Di Nicolantonio, Federica; Longley, Daniel B.; Lawler, Mark
16Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer2009Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
17Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer2014S. Misale;S. Arena;S. Lamba;G. Siravegna;A. Lallo;S. Hobor;M. Russo;M. Buscarino;L. Lazzari;A. Sartore-Bianchi;K. Bencardino;A. Amatu;C. Lauricella;E. Valtorta;S. Siena;F. Di Nicolantonio;A. Bardelli
18BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer2008Di Nicolantonio F; Martini M; Molinari F; Bianchi AS; Arena S; Saletti P; Mazzucchelli L; Frattini M; Siena S; Bardelli A
19BRAF V600E is a determinant of sensitivity to proteasome inhibitors.2013Zecchin D;Boscaro V;Medico E;Barault L;Martini M;Arena S;Cancelliere C;Bartolini A;Crowley EH;Bardelli A;Gallicchio M;Di Nicolantonio F
20Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment2017Riganti, Chiara***; Lingua, MARCELLO FRANCESCO; Salaroglio, IRIS CHIARA; Falcomatà, Chiara; Righi, Luisella; Morena, Deborah; Francesca, Picca; Oddo, Daniele; Kopecka, Joanna; Pradotto, Monica; Libener, Roberta; Orecchia, Sara; Bironzo, Paolo; Comunanza, Valentina; Bussolino, Federico; Novello, Silvia; Scagliotti, Giorgio Vittorio; DI NICOLANTONIO, Federica***; Taulli, Riccardo***; ***corresponding authors

Dettaglio

DI NICOLANTONIO, Federica 

ONCOLOGIA 

 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2020